SIRPα-antiCD33 and 2xSIRPα-antiCD33 licMABs were evaluated based on their binding specificity, cytotoxic effect and phagocytosis of AML cells in vitro. The gene discussed is SIRPA; the disease is acute myeloid leukemia.